Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

COVID-19 Resources » Vaccine Update » Visitor Policy »

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Trial ID or NCT#

NCT00186316

Status

NOT RECRUITING

Purpose

Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.

Official Title

A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Eligibility Criteria

Ages Eligible for Study: 17 Years to 70 Years

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria:

1. For specimen collection and idiotype protein development: - Must be secretory myeloma with at least .5g/dl serum IgG protein - Clinically stage 2 or 3 multiple myeloma - Karnofsky performance status of 70 or greater 2. For Vaccination: - Eligible patients must have completed tandem autologous and nonmyeloablative allogeneic transplant for multiple myeloma at Stanford University Medical Center with stable disease or complete response to prevaccine therapy - Karnofsky performance status of 70 or greater. - ALT and AST must be <2X upper limit of normal. Total bilirubin < 1.5X upper limit of normal. - Serum creatinine <1.5X upper limit of normal. - Hemoglobin >9g/dl - Patients must be HIV negative. - Patients must provide signed, informed consent Donor Inclusion Criteria (allo donor is the same donor used for non-myeloablative transplant) - Age >17 years - HIV negative - Must provide signed, informed consent

Exclusion Criteria:

1. For specimen collection and idiotype protein development: - Patients with non-secretory myeloma - Severe psychological or medical illness - Pregnant or lactating women - Subjects with > Grade I toxicity by NCI-CTC v 3.0 - Subjects with prognosis < 6 months 2. For Vaccination: - < 75 mg of idiotype protein purified from the patients serum - < 25 million allogeneic idiotype-pulsed dendritic cells produced for vaccination - Evidence of grade II-IV acute GVHD (defined in section 5E) - Patients with evidence of myeloma disease progression as (defined below) - Severe psychological or medical illness or concomitant medications which may interfere with the study as determined by the clinical investigator - Patients on any other investigational agents - Pregnant or lactating women - Patients on any therapy for multiple myeloma or any chemotherapy drug, or immunomodulatory agent for treatment of multiple myeloma (e.g. thalidomide) - Any patient on more than two of the following immunosuppressive agents or at a dose greater than that indicated for a single immunosuppressive agent: 1. Mycophenolate Mofetil (MMF)- no greater than 1000mg twice a day 2. Prednisone- no greater than .5mg/kg/day 3. Cyclosporine- no greater than 300mg/day 4. Tacrolimus (FK506)- no greater than 4mg/day

View All Criteria

Investigator(s)

Sally Arai

Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Judith Shizuru

Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist, Hematologist-Oncologist

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)

Robert Lowsky

Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

CONTACT

BMT Referrals
(650) 723-0822

SEND MESSAGE

View on ClinicalTrials.gov

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To:

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To: